KLOW blend peptide ingredients

The KLOW peptide blend contains four compounds — BPC-157, GHK-Cu, TB-500, and KPV — each targeting a distinct layer of the biological repair process. This page breaks down what each ingredient does, why it's included at its specific dose, and what the published research says about its mechanism. Each compound has a deep research base as a standalone peptide; KLOW brings them together into a coordinated regenerative system.

BPC-157 in the KLOW blend (10–15 mg)

BPC-157 (Body Protection Compound 157) is the tissue-repair engine of the KLOW blend. It's a synthetic 15-amino-acid peptide originally isolated from human gastric juice by Professor Predrag Sikirić's research group at the University of Zagreb. BPC-157 has been studied in over 100 preclinical trials across virtually every tissue type — tendon, muscle, ligament, bone, gut mucosa, skin, nerve, and blood vessels.

The primary mechanism of BPC-157 is the promotion of angiogenesis — the formation of new blood vessels — through activation of the VEGFR2 signaling pathway. When tissue is damaged, blood supply to the injury site is often compromised. BPC-157 accelerates the growth of new vasculature, which delivers oxygen, nutrients, and repair cells to the damaged area faster than the body would do on its own. BPC-157 also activates the FAK-paxillin pathway (which regulates how cells adhere to and migrate through tissue), the nitric oxide system (which controls blood vessel dilation), and the JAK-2/STAT3 pathway (which mediates growth factor signaling).

In the context of the KLOW blend, BPC-157 functions as the primary repair initiator — it gets blood flowing to the injury, recruits repair cells, and accelerates the early stages of healing. It pairs particularly well with TB-500, which handles the later-stage coordination of cell migration and tissue remodeling. For a comprehensive deep dive into BPC-157's mechanism, dosing, side effects, and clinical trial status, see the full BPC-157 research guide.

GHK-Cu in the KLOW blend (50 mg)

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is the matrix-remodeling component of the KLOW blend and is present at the highest dose — 50 mg — reflecting both its shorter biological half-life and its role as the primary structural repair agent. GHK-Cu is a naturally occurring tripeptide found in human plasma, saliva, and urine. Plasma concentrations decline significantly with age, from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60, which has led to its investigation as an anti-aging compound.

GHK-Cu's mechanism centers on gene expression regulation. Studies have shown that GHK-Cu modulates the expression of over 4,000 genes — roughly 6% of the human genome. The most relevant effects for the KLOW blend are the upregulation of collagen synthesis (types I and III), elastin production, glycosaminoglycan synthesis (the ground substance that fills the space between cells), and decorin (a proteoglycan that regulates collagen fibril assembly). GHK-Cu also stimulates the production of metalloproteinases that break down damaged extracellular matrix, clearing the way for new, properly organized tissue.

Within the KLOW blend, GHK-Cu handles the structural rebuild phase that follows the initial repair response triggered by BPC-157 and TB-500. While BPC-157 and TB-500 get repair cells to the injury and coordinate their activity, GHK-Cu ensures the new tissue is built with proper collagen architecture rather than disorganized scar tissue. For the full GHK-Cu research library, see the GHK-Cu peptide guide.

TB-500 in the KLOW blend (10–15 mg)

TB-500 is a synthetic version of thymosin beta-4, a 43-amino-acid peptide involved in cell motility and tissue repair. Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian cells, where its primary function is regulating actin — the protein that forms the cytoskeleton and enables cells to move, change shape, and divide. When tissue is damaged, cells at the wound margin need to migrate into the injury site to begin repair. TB-500 facilitates this migration by promoting actin polymerization and reorganization.

Beyond cell migration, TB-500 promotes angiogenesis through a mechanism that is complementary to but distinct from BPC-157's. While BPC-157 primarily works through VEGFR2 signaling, TB-500 promotes blood vessel formation through direct interaction with endothelial cells and the upregulation of vascular endothelial growth factor. The two compounds together produce a more robust angiogenic response than either alone, which is the core rationale for combining them in the Wolverine Blend — and by extension, in KLOW.

TB-500 also has documented anti-inflammatory properties, including the suppression of pro-inflammatory cytokines at the wound site. In the KLOW blend, TB-500 serves as the logistics coordinator — ensuring repair cells arrive where they're needed, organizing the cellular response, and supporting the formation of new vasculature alongside BPC-157.

KPV in the KLOW blend (10 mg)

KPV is the anti-inflammatory component of the KLOW blend. It's a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Alpha-MSH is a neuropeptide with broad anti-inflammatory effects, but its full-length form also has melanotropic activity (it darkens skin) and affects appetite. KPV retains the anti-inflammatory properties of α-MSH while lacking the melanotropic effects — making it useful as a targeted anti-inflammatory agent.

KPV's mechanism centers on the inhibition of NF-κB, the master transcription factor that controls the expression of most pro-inflammatory genes. When NF-κB is activated (by injury, infection, or chronic stress), it upregulates the production of inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. KPV suppresses this cascade at the nuclear level, reducing the inflammatory environment without completely shutting down the immune response (which would impair healing).

In the KLOW blend, KPV's role is to manage the inflammatory environment while the other three compounds handle repair and remodeling. Excessive inflammation impairs healing — it destroys newly forming tissue, delays collagen deposition, and prolongs recovery. By controlling inflammation without suppressing it entirely, KPV creates conditions where BPC-157, TB-500, and GHK-Cu can work more effectively. KPV has also shown particular promise for gut inflammation, including preclinical data in colitis models, which complements BPC-157's well-documented gut-healing properties. For the full KPV research library, see the KPV peptide guide.

Why the KLOW peptide combines these four compounds

The KLOW blend was designed around a simple principle: biological repair requires multiple simultaneous processes, and a single peptide can only address one or two of them. The four compounds in KLOW map to four distinct but overlapping phases of tissue repair.

The synergy is not just additive — the compounds create conditions that make each other more effective. KPV's inflammation control means BPC-157 and TB-500 are working in a less hostile environment. BPC-157's angiogenesis means GHK-Cu has better nutrient supply for matrix synthesis. TB-500's cell migration means repair cells reach the injury faster. And GHK-Cu's matrix remodeling ensures the end result is functional tissue, not scar.